Anatomic Pathology Market Business Opportunities including Key Players Forecast till 2026

According to the new market research report "Anatomic Pathology Market by Product & Service (Instruments (Cell Processor, Microtome), Consumable, Histopathology, Cytopathology, Application (Disease Diagnosis (Cancer (Breast, Lung), End User (Hospital Laboratories), Region - Global Forecasts to 2026", published by MarketsandMarkets™, the market is projected to reach USD 49.1 billion by 2026 from USD 35.1 billion in 2021, at a CAGR of 7.0%.

Browse in-depth TOC on "Anatomic Pathology Market"
491 – Tables
45 – Figures
343 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137323145

The growth of the anatomic pathology market is majorly driven by the high incidence of cancer and other target diseases, recommendations for cancer screening, availability of reimbursement, and the growing focus on personalized medicine. In addition, emerging economies such as China, India, and Brazil are expected to offer significant growth opportunities for players operating in the anatomic pathology market during the forecast period.

Drivers: High incidence of cancer and other target diseases

Cancer is the second-leading cause of death worldwide, accounting for 10 million deaths in 2020. Globally, about 1 in 6 deaths occur due to cancer (Source: World Health Organization). In 2020, 19.3 million new cancer cases were reported, and this figure is expected to increase to 30.2 million by 2040. This increase in the incidence of cancer can be attributed to the growing geriatric as well as the total population.

According to the World Population Ageing 2020 report, the global population aged 65 years and above was 727 million in 2020 and is expected to double by 2050 to reach 1.5 billion. Since the elderly are more susceptible to various diseases, this demographic trend is expected to result in a significant growth in the prevalence of several chronic diseases, including cancer, across the globe.

The incidence of cancer is the highest in developed regions; however, cancer mortality is relatively higher in underdeveloped regions due to a lack of access to treatment facilities and the late detection of cancer in several patients. According to the WHO, for many cancers, the incidence rate in countries with high or very high HDI1 is generally 2–3 times that of low- or medium-HDI countries. Approximately 70% of deaths due to cancer were reported in low-income and middle-income countries in 2018.

Opportunities: Increasing number of clinical trials pertaining to cancer drugs

Anatomic pathology products and services are used in oncology drug trials to analyze quantitative information, detect morphological structures, detect pharmacodynamic markers, and understand drug mechanisms. It is also used to stratify trial subjects based on the responses given by tissues to the drugs. Tissue diagnostics thus enable efficient trials and retrospective studies by reducing the cost and time involved in these processes. For example, in a Phase III study for Roche’s cancer immunotherapy—TECENTRIQ (atezolizumab)—the PD-L1 (programmed death-ligand 1) expression was assessed using an investigational immunohistochemistry (IHC) test, which was developed by Roche Tissue Diagnostics.

Key Market Players

The global anatomic pathology market for instruments and consumables is consolidated. The top five companies in this market are F. Hoffmann-La Roche AG (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Beckton, Dickson and Company (US), and Abcam plc. (UK).

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=137323145

F. Hoffmann-La Roche AG (Switzerland) was the leading player in the anatomic pathology market in 2020. The company has a wide range of products in the consumables segment. Strong business operations across all key regions, coupled with a strong brand image, make the firm a leading player in this market. F. Hoffman-La Roche has adopted organic business strategies such as product launches in order to maintain its leading position in the anatomic pathology market. For instance, in 2020, the company received FDA approval for its CINtec PLUS Cytology test. Similarly, in 2018, the company received CE approval for its BenchMark ULTRA Plus staining system.

Danaher Corporation (US) was the second-leading player in the anatomic pathology market in 2020. The company has a broad product portfolio in the instruments segment. Moreover, Danaher also has a strong geographic presence with its direct distribution channels across the globe. The impressive product portfolio of the firm is complemented by its client support services. Over the years, Danaher has maintained its leading position in the market through continuous innovation and the launch of advanced products. For example, in 2018, Danaher launched various clinical microtomes, such as the HistoCore BIOCUT, HistoCore MULTICUT, and HistoCoreAUTOCUT clinical microtomes.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=137323145

Related Reports:

Anatomic Pathology Market by Product & Service (Instruments (Cell Processor, Microtome), Consumable, Histopathology, Cytopathology, Application (Disease Diagnosis (Cancer (Breast, Lung), End User (Hospital Laboratories), Region - Global Forecasts to 2026

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Article source: https://article-realm.com/article/Health-Fitness/Exercise/35789-dahAnatomic-Pathology-Market-Business-Opportunities-including-Key-Players-Forecast-till-2026.html